Cost-Effectiveness (Cost-UtilityAnalysis)

1. Brown GC, Sharma S, Brown MM, Garrett S. Evidence-based medicine and cost-effectiveness. J Healthcare Fin 1999;26:14-23.

2. Brown GC, Brown MM, Sharma S, Tasman W, Brown H. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999;104(4):e47.

3. Brown GC, Sharma S, Brown MM, Garrett S. Evidence-based medicine and cost-effectiveness. J Healthcare Fin 1999;26:14-23.

4. Brown GC, Brown MM, Sharma S, Tasman W, Brown H. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999;104(4):e47.

5. Shah G, Sharma S, Brown GC. Choroidal neovascularization following argon laser photocoagulation for macular edema associated with branch retinal vein obstruction. Can J Ophthalmol 2000;35:437-430.

6. Sharma S, Hollands H, Brown GC, Brown MM, Shah G, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy Curr Opin Ophthalmol 2001;12:230-234.

7. Brown GC, Brown MM. Is prophylactic PRP in ischemic CRVO a good idea? Rev Ophthalmology 2000, 7:106,108,111.

8. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiology 2002;9:1-10.

9. Membreno J, Brown MM, Brown GC, Sharma S, Beauchamp G. A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002;109:2265-2271.

10. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059.

11. Busbee B, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002;109:606-612.

12. Brown GC, Brown MM, Sharma S, Busbee B. A cost-utility analysis of interventions for proliferative vitreoretinopathy. Am J Ophthalmol 2002;133:365-372.

13. Fineman MS, Vander J, Regillo CD, Fineman SW, Brown GC. Hypopyon uveitis in immunocompetent patients treated for Mycobacterium avium complex pulmonary infection with rifabutin. Retina 2001;21:531-533.

14. Benson WE, Regillo CD, Vander JF, Tasman W, Smith AF, Brown GC, Ho AC, McNamara JA. Patient-initiated second medical opinions: Their necessity and economic cost. Retina 2001;21:633-638.

15. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003;110:2310-2317.

16. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003;23:279-287.

17. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular age-related macular degeneration. A reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687.

18. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration Ophthalmology 2007;114:1170-1178.

19. Beauchamp CL, Beauchamp GR, Felius J, Stager DR, Brown G, Brown M, Felius J. The cost-utility of strabismus surgery in adults J Am Soc Ped Ophthalmol 2007:10:394-9.

20. Brown GC, Brown MM, Brown H, Peet JS. A value-based medicine analysis of ranibizumab (MARINA Study) for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008;115:1039-1045.

21. Gupta O, Brown GC, Brown MM. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery. Am J Ophthalmol. 2008;145:923-8. Epub 2008 Mar 10.

22. Roe RH, Lass JH, Brown GC, Brown MM. The cost-effectiveness of penetrating keratoplasty for keratoconus. Cornea (in press).

23. Brown GC, Brown MM, Sharma S. Cost-effective analysis can help improve the U.S. health care system. Ocular Surgery News, Asia-Pacific Edition, 2001;12:40-41.

24. Brown GC, Brown MM. Factoring treatment cost into retina therapy. What should be the priorities for vitreoretinal inteventions? And at what cost? Rev Ophthalmol, Vol 14, 9-7-2007.

25. Brown MM, Brown GC ,Brown HC, Irwin B, Brown KS. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions. Curr Opin Ophthalmol 2008;19:202-207.

26. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-utility of treatment for acute, non-arteritic central retinal artery obstruction. Evidence-Based Eye 2000;1:243-247.

27. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-utility analysis of cataract surgery utilizing decision analysis Evidence-Based Eye Care. 2000;1:297-301.

28. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-effective analysis: Cataract surgery and sensitivity analysis. Evidence-Based Eye Care 2001;2:55-59.

29. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-effective analysis: Diabetic vitrectomy. Evidence-Based Eye Care 2001;2:117-121.